Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-110745-72201cc8",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n# SCFA Brain Concentrations & HDAC Inhibition - Synthesis Analysis\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"id\": \"H3\",\n      \"title\": \"GPR109A as Primary Mechanism for Microglial Reprogramming\",\n      \"target\": \"HCAR2 (GPR109A/Niacr1)\",\n      \"composite_score\": 0.835,\n      \"mechanistic_plausibility\": 0.80,\n      \"evidence_strength\": 0.85,\n      \"novelty\": 0.75,\n      \"feasibility\": 0.85,\n      \"therapeutic_potential\": 0.90,\n      \"druggability\": 0.90,\n      \"safety_profile\": 0.75,\n      \"competitive_landscape\": 0.80,\n      \"data_availability\": 0.85,\n      \"reproducibility\": 0.85,\n      \"evidence_for\": [\n        {\"claim\": \"GPR109A is a high-affinity receptor for niacin and butyrate (Kd ~100 nM)\", \"pmid\": \"11707776\"},\n        {\"claim\": \"Microglia express functional GPR109A\", \"pmid\": \"25601787\"},\n        {\"claim\": \"GPR109A activation suppresses microglial inflammation via HDAC-dependent mechanisms\", \"pmid\": \"26296954\"},\n        {\"claim\": \"Oral butyrate improves neuroinflammation at μM plasma concentrations\", \"pmid\": \"27453500\"},\n        {\"claim\": \"GPR109A agonists (niacin, acifran, MK-6892) have established SAR and multiple tool compounds\", \"pmid\": \"29307019\"},\n        {\"claim\": \"No CNS-focused GPR109A program exists - open competitive field\", \"pmid\": \"30816739\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"GPR109A-independent HDAC inhibition may contribute to therapeutic effects\", \"pmid\": \"28629854\"},\n        {\"claim\": \"Niacin's side effects (flushing, hepatotoxicity) may limit therapeutic window\", \"pmid\": \"29947770\"}\n      ],\n      \"key_insight\": \"Resolves the nM-μM vs mM disconnect - GPR109A operates at concentrations achievable via oral supplementation while HDAC inhibition requires unachievable concentrations. This represents a paradigm shift, not a contradiction.\"\n    },\n    {\n      \"rank\": 2,\n      \"id\": \"H2\",\n      \"title\": \"Prebiotic Enhancement of SCFA Production\",\n      \"target\": \"Microbial butyrate synthesis pathway (butyryl-CoA:acetate CoA-transferase, but gene cluster)\",\n      \"composite_score\": 0.445,\n      \"mechanistic_plausibility\": 0.55,\n      \"evidence_strength\": 0.50,\n      \"novelty\": 0.45,\n      \"feasibility\": 0.40,\n      \"therapeutic_potential\": 0.35,\n      \"druggability\": 0.15,\n      \"safety_profile\": 0.75,\n      \"competitive_landscape\": 0.25,\n      \"data_availability\": 0.70,\n      \"reproducibility\": 0.40,\n      \"",
  "tokens_used": "603",
  "persona_id": "persona-synthesizer"
}